This CE presentation will provide a review of heart failure pathophysiology, risk factors, the current non-pharmacologic/pharmacologic recommendations, with supporting clinical trials and the presentation of clinical trials of ivabradine and valsartan/sacubitril with a discussion on their place in HF treatment. A review of recommendations for management of acute decompensated heart failure will also be presented.
Shenandoah University Bernard J. Dunn School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Requirements for CE Credit
- Select the most appropriate description of the pathophysiology of heart failure
- Select the most appropriate non-pharmacologic & pharmacologic recommendations for chronic HF, given a scenario
- Identify the mechanism of action and common side effects of the new HF agents
- Identify key findings of the new HF drug studies by selecting the best pharmacotherapy recommendation, given the clinical scenario
Vanessa Pierre, PharmD
Brief Bio : Dr. Vanessa Pierre is a PGY-1 Pharmacy Practice Resident at Winchester Medical Center. Her professional interests include oncology, cardiology, critical care, quality improvement initiatives and clinical research. Dr. Pierre earned her Doctorate of Pharmacy degree from the University of Maryland in Baltimore in May 2015. She earned her Bachelor of Science degree in Biology from Nova Southeastern University, Florida, in 2009. Dr. Pierre is a member of the American Society of Health-System Pharmacists and the National Pharmaceutical Association. In her free time she enjoys outdoor activities, going to the beach, spending time with friends and family, traveling and learning how to play the piano.
Release Date: Apr 4, 2016
Credit Expiration Date: Apr 4, 2019
Health Professions Building RM 109